Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.06 USD | -0.75% | +5.37% | -34.19% |
May. 09 | Earnings Flash (RKDA) ARCADIA BIOSCIENCES Reports Q1 Revenue $1.26M, vs. Street Est of $1.19M | MT |
May. 09 | Transcript : Arcadia Biosciences, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Ratings chart - Surperformance
Sector: Agricultural Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-34.19% | 2.81M | - | ||
+19.95% | 40.06B | C | ||
-.--% | 11.1B | - | B+ | |
+7.11% | 8.43B | A | ||
+1.35% | 6.46B | B- | ||
-2.09% | 6.16B | B+ | ||
-5.87% | 5.61B | B | ||
+37.82% | 5.46B | B- | ||
-18.11% | 5.11B | - | C- | |
-14.56% | 4.51B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- RKDA Stock
- Ratings Arcadia Biosciences, Inc.